The way large food companies respond to regulatory pressure in the U.S. has fundamentally changed in the last twelve months. On April 23, 2026, Aldi announced it would eliminate 44 ingredients from every private-label food, vitamin, and supplement product on its U.S. shelves by December 2027. Preservatives, artificial sweeteners, dough conditioners, colorants — most of them banned years ago in Europe, Canada, and Japan, most of them still legal here. Walmart announced something similar last fall. Save A Lot in January. Target on cereals. PepsiCo on Doritos and Cheetos. Mars on Skittles. Campbell’s pledged a full synthetic-color exit by mid-fiscal 2026.
The headline reads like a clean-label news cycle. The story underneath is bigger: the way large food companies respond to regulatory pressure in the U.S. has fundamentally changed in the last twelve months, and it’s reshaping how corporate R&D operates.
How the food industry avoided reformulation for 60 years
For sixty years, the U.S. food industry’s first move when an ingredient came under scrutiny was structural delay. The 1958 Food Additives Amendment created the GRAS pathway — “Generally Recognized as Safe” — which was meant to cover obvious things like vinegar and black pepper. A 1997 rule change let companies self-certify any ingredient as GRAS without telling the FDA. Between 1990 and 2010, around 1,000 ingredient-safety decisions were made by manufacturers and never reported to the FDA at all. Another 2,700 were certified by industry expert panels. By the FDA’s own accounting, manufacturers and trade associations made roughly 60% of the 6,000 safety decisions allowing substances into U.S. food during that window.
When public pressure built around a specific ingredient, the response was almost always layered: lobby federal regulators to maintain the status quo, lobby states against bans, adjust labels to obscure rather than remove, and in the worst case, swap to a chemically similar cousin that wasn’t yet on the public radar. Reformulation — actually changing what’s in the product — was the last resort, used reluctantly and usually only in markets where it was legally forced (which is why the European version of a Kellogg’s cereal looks different from the American one).
That playbook still exists. In October 2025, Coca-Cola, PepsiCo, General Mills, Nestlé and other major CPGs formed a coalition called Americans for Ingredient Transparency. The FRESH Act, introduced in Congress this April, would lock in significant carve-outs to FDA pre-market review and tilt oversight toward a reactive post-market model. Industry isn’t done lobbying. But — and this is the shift — they’re no longer only lobbying.
Three forces that made the old strategy impossible
The patchwork made delay impossible. California passed the Food Safety Act in October 2023, banning four additives starting in 2025. By 2025, roughly 75 food-dye bills had been introduced in 37 states. West Virginia, Texas, Virginia, Utah and others followed with varying restrictions. For a national CPG, “wait it out” stops working when twelve different state regimes go live in eighteen months. You either reformulate a single national SKU or maintain a dozen state-specific manufacturing runs. The math forces the first option.
The federal posture flipped. In April 2025, HHS and FDA jointly announced a phase-out of all petroleum-based synthetic dyes by end of 2026, with FDA moving to revoke authorizations for Citrus Red No. 2 and Orange B and pressuring industry to voluntarily drop the rest. RFK Jr. has openly targeted GRAS reform itself; a proposed rule is currently sitting at OMB. The same agency that, for decades, was the industry’s argument against state action (“trust the federal process”) is now actively pushing in the same direction the activists are.
Retailers moved before brands. This is the part most people miss. Aldi, Walmart, Target, and Save A Lot didn’t reformulate because regulators forced them to. They moved on private label, the products they control, to capture clean-label positioning before their suppliers caught up. That created a downstream pull on ingredient suppliers and contract manufacturers that’s now bigger than the regulatory push. When Walmart says “no synthetic dyes in our private brand by January 2027,” it calls the move “one of the largest private brand reformulations in retail history” — every contract manufacturer that supplies that private brand has to figure out how, fast.
What reformulation at scale actually costs R&D teams
Reformulating a single SKU is hard. Reformulating thousands of SKUs across the industry, on overlapping deadlines, against an undersupplied alternative-ingredient market, is something close to an industry-wide R&D restructuring.
A few numbers from the supply side. The global natural food colors market was estimated at around $2 billion in 2025, projected to roughly double over the next decade, with North America growing fastest. Sensient is expanding its largest natural-color plant in St. Louis. Oterra, the world’s largest natural-color producer, partnered with VAXA Technologies on a fermentation-derived blue. ADM, IFF, Givaudan, Kerry, DSM-Firmenich, and Symrise are all investing in application labs that co-develop with major food brands — because, as IFF puts it, “shifting from synthetic to natural food color is rarely a one-to-one exchange”. Each reformulation is a custom project, not a shelf swap.
That last point is the one corporate R&D leaders are now wrestling with. Synthetic Red 40 has a single chemical structure with predictable behavior across pH, heat, and shelf life. Replace it with a natural alternative — anthocyanins, beet, carmine, butterfly pea — and you’re now managing a botanical raw material with seasonal variability, different stability under processing, different cost curves, different supply chain risk. Multiply that across colors, preservatives, sweeteners, emulsifiers, and you have a multi-year program where the bottleneck isn’t ideas — it’s finding suppliers, validating performance, and locking in supply before the deadline.
Some of the biggest food companies have publicly said FDA’s natural-color timeline may not even be feasible at industry scale, citing supply constraints. Bluegrass Ingredients, a clean-label supplier that’s been watching this from the trenches, argues this moment is genuinely different from past reformulation cycles: “We’ve had other mass reformulations in the past, but those were driven by regulations or consumer behavior, not both.”
How corporate food R&D is being restructured
Two structural shifts are showing up in how food and beverage R&D teams are being run.
The first is a rebalancing between internal R&D and external scouting. The traditional CPG R&D org spent most of its time on incremental NPD — line extensions, new flavors, new pack formats. The reformulation backlog has moved a meaningful share of R&D capacity onto ingredient substitution work, which is closer to applied chemistry than to product development. And because no internal team has the bandwidth to scout, qualify, and validate dozens of new ingredient suppliers in parallel, external partnership is doing more of the load: ingredient suppliers’ application labs, university food science programs, fermentation and biotech startups, even cosmetics-ingredient companies whose botanical actives turn out to have food-grade analogues.
The second is a flattening of the regulatory-vs-innovation distinction. Historically, regulatory affairs and R&D sat in different rooms. Reg-affairs handled the lobbying and labeling; R&D worked on the next launch. The reformulation wave is fusing them. The decision about which alternative ingredient to source, at what price point, with what label claim, is now simultaneously a regulatory bet (will this hold up across 50 states and a moving FDA target?), a supply-chain bet (can we get enough of it by 2027?), and an R&D bet (will it perform in our matrix?). Companies that can integrate those three layers are moving faster than companies still treating them as sequential handoffs.
The bigger shift behind the clean-label wave
Step back, and the Aldi announcement is best read as a single visible data point in a much larger reordering. For most of the last sixty years, the U.S. food system worked on an implicit deal: ingredient innovation lived inside CPG companies, regulatory pace was slow enough to be managed, and consumer demand was elastic enough to be steered by marketing. All three premises are bending at the same time.
Ingredient innovation is migrating outside the big CPGs and into a thicker layer of specialist suppliers, biotech firms, and academic labs. Regulatory pace just accelerated dramatically and is no longer reliably federal-first. And consumer demand, for the first time in this category, is moving faster than either regulators or brands, with retailers (not manufacturers) acting as the transmission mechanism.
The 44 ingredients on Aldi’s list are the easy-to-photograph version of all of that. The harder version is happening inside R&D org charts and supplier contracts that won’t make a press release. By the time the December 2027 deadline arrives, the more durable change won’t be which preservatives are or aren’t in a bag of Aldi pretzels. It’ll be the way the next decade’s worth of ingredient innovation gets sourced, validated, and brought to market — and how much of that work happens outside the four walls of the company whose name is on the package.
